Drug Profile
Research programme: viral vaccines - CPL Biologicals
Alternative Names: Recombinant nanoparticle vaccines - CPL BiologicalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Novavax
- Developer CPL Biologicals
- Class Protein vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rabies; Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rabies in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in India (Parenteral)
- 22 Jan 2014 Rabies G protein vaccine has entered clinical development in India